Skip to main content
< Back
About
About the conference
Latest updates
Organisers & Partners
App
Press room
Programme 19
Full programme
Tracks
Speakers 19
Keynote speakers
All speakers
Side events 19
Venue 19
About the venue
Location
Rooms
Subscribe
Treatment: medical/pharmacological
Sessions
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Alcohol and drug treatment
Opioid-related deaths: current and emerging lessons
Monitoring — Treatment: medical/pharmacological
Opiates — Treatment: medical/pharmacological
Overdose — Treatment: medical/pharmacological
Treatment: medical/pharmacological — Alcohol
Wednesday, 23 October
10:50
Understanding and improving health and social outcomes
10:50
to
12:20
Networking zone 3 (N3)
Sanna Rönkä
Policy, practice and patient care
Depot medications for unmet treatment needs in opioid use disorder
10:50
to
12:20
Networking zone 2 (N2)
Michelle Lofwall
Definition of disorders
10:50
to
12:20
Networking zone 1 (N1)
Viktor Mravčík
Poster guided tour
Progress in alcohol research and responses - EUFAS poster session 1
10:50
to
12:20
Guided poster tours room
Colin Drummond
13:20
Treatment — challenges, determinants and responses
13:20
to
14:50
Networking zone 3 (N3)
Dominique Lopez
15:00
Progress in alcohol research and treatment
15:00
to
16:30
Main stage
Emanuele Scafato
Epidemiology of hepatitis C among people who use drugs — Data to inform future planning
15:00
to
16:30
Insights zone 3 (I3)
Vana Sypsa
Jack Stone
Improving responses to opioid-related harm
15:00
to
16:30
Central square 3 (C3)
Steve Gust
Therapeutic horizons I
15:00
to
16:30
Networking zone 1 (N1)
Wouter Vanderplasschen
16:50
Extending the evidence-base of opioid substitution treatment
16:50
to
18:20
Insights zone 4 (I4)
John Marsden
18:30
Workforce development and training
18:30
to
19:30
Networking zone 3 (N3)
Andrew Bennet
Thursday, 24 October
10:50
Towards a consensus approach to opioid substitution treatment outcomes and how they are monitored
10:50
to
12:20
Networking zone 1 (N1)
Lucas Wiessing
Alcohol perspectives and prevention - EUFAS poster session 2
10:50
to
12:20
Guided poster tours room
Linn Gjersing
13:20
Cannabis — risks and responses
13:20
to
14:50
Networking zone 4 (N4)
Jennifer Price
Evidence to guide future practice and policy
Enhancing hepatitis C treatment outcomes among people who use drugs
13:20
to
14:50
Insights zone 1 (I1)
Catharina Matheï
Adrian Dunlop
Focus on prescription drugs I
13:20
to
14:50
Insights zone 3 (I3)
Volker Auwärter
Treatment adherence
13:20
to
14:50
Insights zone 4 (I4)
Marta Torrens Melich
15:00
Youth pathways
15:00
to
16:30
Networking zone 2 (N2)
Gregor Burkhart
16:50
New perspectives on cannabis use disorders and their treatment
16:50
to
18:20
Insights zone 4 (I4)
Tom Freeman
Valentina Lorenzetti
Methods and measurement of economic cost of substance use
16:50
to
18:20
Central square 3 (C3)
Rosalie Pacula
Striving towards the future elimination of Hep C among people who use drugs
16:50
to
18:20
Futures zone 1 (F1)
Eberhard Schatz
Perrine Roux
18:30
Opioids — current and emerging lessons
18:30
to
19:30
Networking zone 4 (N4)
Roumen Sedefov
Friday, 25 October
10:45
Pharmacological Interventions
Young people's addictions treatment
10:45
to
12:15
Networking zone 4 (N4)
Deborah Judge
Lisa Mellen
Treatment — improving standards and outcomes
10:45
to
12:15
Networking zone 3 (N3)
Gerhard Bühringer
Alcohol: alcohol use disorder treatment and outreach
10:45
to
12:15
Insights zone 1 (I1)
Colin Drummond
Presentations
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Wednesday, 23 October
10:50
Oral presentation
European policy issues that affect OUD treatment access
10:50
to
11:05
Networking zone 2 (N2)
Gabriele Fischer
Poster
Exposure to alcohol and/or cadmium changes status of bioelements in rat tests
10:50
to
12:20
Guided poster tours room
Mirjana Djukic
Poster
'Drink to forget' – a case report
10:50
to
12:20
Guided poster tours room
Mariana Lázaro
Poster
Screening for alcohol-related cognitive impairments – a case study
10:50
to
12:20
Guided poster tours room
Luisa Gil
Poster
Neuroprotective role of argan oil against alcohol use disorders in adolescent wistar rat
10:50
to
12:20
Guided poster tours room
Hicham El Mostafi
Poster
Cadmium and/or ethanol increase oxidative stress in liver of the exposed rats
10:50
to
12:20
Guided poster tours room
Mirjana Djukic
Poster
Screening and brief interventions for reducing alcohol consumption in a department of firefighters in the central region of Portugal
10:50
to
12:20
Guided poster tours room
Teresa Barroso
Poster
Court proceedings and actions taken by a probation officer in work with people addicted to alcohol.
10:50
to
12:20
Guided poster tours room
Ewelina Silecka-Marek
Poster
Elderly wellbeing and alcohol - a tricky cocktail
10:50
to
12:20
Guided poster tours room
Jakob Emiliussen
11:00
Short communication
Portuguese gender-sensitive harm reduction services: bridging the gap
11:00
to
11:10
Networking zone 3 (N3)
Oral presentation
Views about the disease and brain disease model of addiction: an international survey of addiction treatment providers in the USA, UK and Australia
11:00
to
11:15
Networking zone 1 (N1)
Anthony Barnett
11:05
Oral presentation
Overview of potential benefits of depot therapies, reviewing several newer buprenorphine depot formulations including the 6-month implants
11:05
to
11:30
Networking zone 2 (N2)
Michelle Lofwall
11:10
Short communication
A change in the prescribing practice of prebagalin that has had a direct negative effect on drug-induced deaths in Ireland
11:10
to
11:20
Networking zone 3 (N3)
Ena Lynn
11:15
Oral presentation
Reconsidering cannabis dependence
11:15
to
11:30
Networking zone 1 (N1)
Liz Temple
11:30
Short communication
Performance enhancing drugs. Results from a Belgian survey on PED use among workers
11:30
to
11:40
Networking zone 3 (N3)
Marie-Claire Lambrechts
Oral presentation
Agreement degree with the content of the Substance Addiction Consequences Scale items - The development of a new instrument.
11:30
to
11:45
Networking zone 1 (N1)
Paulo Seabra
Oral presentation
Open-label safety study conducted in Europe, Australia and the US
11:30
to
11:55
Networking zone 2 (N2)
Genie Bailey
11:40
Short communication
Drug and alcohol treatment: how much does it cost in Europe?
11:40
to
11:50
Networking zone 3 (N3)
Claudia Costa Storti
11:45
Oral presentation
Characterising people that demanded drug treatment in Catalonia: a cluster analysis
11:45
to
12:00
Networking zone 1 (N1)
Xavier Majó
11:50
Short communication
Young people's exposure to gambling advertisements: a mixed methods study in Australia.
11:50
to
12:00
Networking zone 3 (N3)
Hannah Pitt
11:55
Oral presentation
The implications for European patients, practice and policy
11:55
to
12:20
Networking zone 2 (N2)
Gabriele Fischer
Sharon L. Walsh
12:00
Short communication
Street Work Nursing as an innovative strategy in the care for dually diagnosed individuals: reflections on a pilot study
12:00
to
12:10
Networking zone 3 (N3)
Ilse Goethals
12:10
Short communication
Dissuasion, the effectiveness of the intervention and good practices
12:10
to
12:20
Networking zone 3 (N3)
Américo Gegaloto
13:30
Short communication
Treating drug abuse and health issues in the criminal justice system. An empirical research on the linkage of health and criminal justice interventions, France
13:30
to
13:40
Networking zone 3 (N3)
Ivana Obradovic
Short communication
Perceptions on social determinants of opioid dependence recovery
13:30
to
13:40
Networking zone 3 (N3)
Leonor Brito
13:40
Short communication
Reverse transition from injecting to smoking heroin and/or crack cocaine on lower methadone dose: sub-therapeutic dosing or safer drug use?
13:40
to
13:50
Networking zone 3 (N3)
Felicia Heidebrecht
13:50
Short communication
Benzodiazepine management in primary care: barriers and facilitators
13:50
to
14:00
Networking zone 3 (N3)
Kristien Coteur
14:00
Short communication
Referral of European and third country non-national clients in Belgian drug treatment
14:00
to
14:15
Networking zone 3 (N3)
Eva Blomme
14:10
Short communication
HIV and drug abuse: relationship and treatment challenges
14:10
to
14:20
Networking zone 3 (N3)
Sara Dehanov
14:20
Short communication
Motivation for treatment predict adherence to treatment in a randomised clinical trial
14:20
to
14:30
Networking zone 3 (N3)
Zhanna Gaulen
14:30
Short communication
Psychiatric assessment of prisoners in opioid-maintenance treatment: emphasis on ADHD
14:30
to
14:40
Networking zone 3 (N3)
Marisa Silbernagl
14:40
Short communication
Perceptions on social determinants of opioid dependence recovery
14:40
to
14:50
Networking zone 3 (N3)
15:00
Oral presentation
The contribution of injecting drug use as a risk factor for Hepatitis C virus transmission globally, regionally, and at country level: a modelling study
15:00
to
15:15
Insights zone 3 (I3)
Adam Trickey
15:10
Oral presentation
A peer-led integrated approach for co-existing mental and addictive disorders: a longitudinal qualitative study of the first UK dual diagnosis anonymous
15:10
to
15:25
Networking zone 1 (N1)
Raffaella Margherita Milani
Oral presentation
The evolving opioid overdose crisis and the rising role of methamphetamine
15:10
to
15:25
Central square 3 (C3)
Christopher Jones
Oral presentation
Guidelines AUD in Europe
15:10
to
15:25
Main stage
Colin Drummond
15:15
Oral presentation
Factors associated with HIV and hepatitis C in the context of routes of drug administration among problem drug users in Latvia, 2018
15:15
to
15:30
Insights zone 3 (I3)
Laura Isajeva
15:25
Oral presentation
m-Health among illicit drug users: effectiveness, differential indication, risks and negative effects and ongoing developments among guided and unguided interventions
15:25
to
15:40
Networking zone 1 (N1)
Michael Schaub
Oral presentation
Examination of emerging adults with opioid use disorders
15:25
to
15:40
Central square 3 (C3)
Holly Hills
Oral presentation
New technologies in AUD treatment
15:25
to
15:40
Main stage
Antoni Gual
15:30
Oral presentation
Barriers in the treatment of HCV infection in drug users: inspiring solutions from SCUDO project
15:30
to
15:45
Insights zone 3 (I3)
Felice Alfonso Nava
15:40
Oral presentation
Associations of ketamine use with mental health and substance use outcomes at 12 months follow-up in young Europeans
15:40
to
15:55
Networking zone 1 (N1)
Meryem Grabski
Oral presentation
Recent non-fatal opioid overdose: the effects of health service utilisation, alcohol and other drug use and demographic factors
15:40
to
15:55
Central square 3 (C3)
Penelope Hill
Oral presentation
Precision medicine in AUD
15:40
to
15:55
Main stage
Geert Dom
15:45
Oral presentation
HCV care in an opiate substitution therapy program: assessment of infection, liver-related damage, and treatment rates.
15:45
to
16:00
Insights zone 3 (I3)
Roberto Muga
15:55
Oral presentation
The acceptability of psychedelics as treatment options in psychiatry. Data from GDS2019
15:55
to
16:10
Networking zone 1 (N1)
Adam Winstock
Oral presentation
In utero opioid exposure and risk of infections in childhood: a multinational Nordic cohort study
15:55
to
16:10
Central square 3 (C3)
Marte Handal
Oral presentation
New thoughts on outcomes in AUD treatment
15:55
to
16:10
Main stage
Karl Mann
16:00
Oral presentation
Slamming, drug injection in sexual contexts: increased HIV and HCV exposure for MSM points to a need for intersectional approaches to harm reduction
16:00
to
16:15
Insights zone 3 (I3)
Marie Jauffret-Roustide
16:10
Oral presentation
Effectiveness and cost-effectiveness of adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial
16:10
to
16:25
Networking zone 1 (N1)
John Marsden
Oral presentation
Reducing inappropriate use of prescription opioids in hospital patients
16:10
to
16:25
Central square 3 (C3)
Erin Winstanley
Oral presentation
Pain in AUD
16:10
to
16:25
Main stage
Marcin Wojnar
16:15
Oral presentation
Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: a systematic review and meta-analysis
16:15
to
16:30
Insights zone 3 (I3)
Jason Grebely
17:00
Oral presentation
Predictors of treatment allocation guesses in a randomised controlled trial testing double-blind injectable hydromorphone and diacetylmorphine for severe opioid use disorder
17:00
to
17:15
Insights zone 4 (I4)
Kirsten Marchand
17:15
Oral presentation
Illicit stimulant use in the context of daily injectable opioid agonist treatment: a grounded theory study with patients receiving treatment for severe opioid use disorder in Vancouver, Canada
17:15
to
17:30
Insights zone 4 (I4)
Heather Palis
17:30
Oral presentation
The effect of entry and retention in opioid substitution therapy on contact with the criminal justice system among opioid dependent people
17:30
to
17:45
Insights zone 4 (I4)
Natasa Gisev
17:45
Oral presentation
Depot buprenorphine for opioid dependence in prisons in NSW, Australia
17:45
to
18:00
Insights zone 4 (I4)
Adrian Dunlop
18:00
Oral presentation
Slow release oral morphine versus methadone for the treatment of opioid use disorder: a systematic review and meta-analysis
18:00
to
18:15
Insights zone 4 (I4)
Jan Klimas
18:30
Short communication
The peer in outreach teams: a specialist among specialists?
18:30
to
18:40
Networking zone 3 (N3)
Maria João Oliveira
18:40
Short communication
The Akan-model: a Norwegian model for preventing and handling alcohol, drugs and gambling problems in the workplace
18:40
to
18:50
Networking zone 3 (N3)
Camilla Lynne Bakkeng
18:50
Short communication
Experiences of marketised welfare organisations among addiction treatment staff in Sweden
18:50
to
19:00
Networking zone 3 (N3)
Jessica Storbjörk
19:00
Short communication
Preparing effective addiction workforce: a challenge from the Czech perspective
19:00
to
19:10
Networking zone 3 (N3)
Amalie Pavlovská
19:10
Short communication
Workforce development: the great paradox for the addictions sector
19:10
to
19:20
Networking zone 3 (N3)
Ann Roche
19:20
Short communication
Evidence-based practice and its many competing priorities: a qualitative analysis of substance misuse workers in English third-sector addiction treatment services
19:20
to
19:30
Networking zone 3 (N3)
Robert Calder
Thursday, 24 October
10:50
Oral presentation
A consensus approach to opioid substitution treatment outcomes and how they are monitored
10:50
to
11:10
Networking zone 1 (N1)
Lucas Wiessing
Poster
Alcohol addiction as a social problem in Ukraine: history of research
10:50
to
12:20
Guided poster tours room
Larysa Klymanska
Poster
The alcohol consumption in the modern Ukraine: tendences and perspecties.
10:50
to
12:20
Guided poster tours room
Larysa Klymanska
Poster
Alcohol and drugs in contemporary school pupils on the verge of adolescence: the Polish experience
10:50
to
12:20
Guided poster tours room
Katarzyna Pawelek
Poster
The role of alcohol in fatal fires in Ireland
10:50
to
12:20
Guided poster tours room
Anne Doyle
Poster
Do parents want to change alcohol legislations to protect their children?
10:50
to
12:20
Guided poster tours room
Marta Zin-Sedek
Poster
Social and context determinants of drinking during working time – Portuguese GPS findings 2017
10:50
to
12:20
Guided poster tours room
Cláudia Urbano
Poster
Sub-groups of tobacco and alcohol co-use trajectories from ages 21 to 32: the Amsterdam growth and health longitudinal study
10:50
to
12:20
Guided poster tours room
Sterling McPherson
Poster
Effects of an alcohol prevention program at sport stadiums: a 2-year follow-up study using pseudopatrons and breath alcohol concentration levels
10:50
to
12:20
Guided poster tours room
Tobias Elgan
Poster
Implementing and evaluating alcohol and drug prevention methods at youth health clinics
10:50
to
12:20
Guided poster tours room
Pia Kvillemo
Poster
Accessing alcohol drinking influence in workplace – What is the panorama and current innovations in Portugal?
10:50
to
12:20
Guided poster tours room
Duarte Vital Brito
11:10
Oral presentation
Quality of life as a monitoring outcome measure for OST
11:10
to
11:15
Networking zone 1 (N1)
Bernd Schulte
11:15
Oral presentation
A routine-outcome-management tool to measure outcome of harm reduction
11:15
to
11:20
Networking zone 1 (N1)
Mads Uffe Pedersen
11:20
Oral presentation
Outreach and low threshold services for health care and drug addiction
11:20
to
11:25
Networking zone 1 (N1)
Hugo Faria
11:25
Oral presentation
Identifying client needs when using treatment monitoring data to inform and improve nursing practice
11:25
to
11:30
Networking zone 1 (N1)
Catherine Comiskey
11:30
Panel discussion
11:30
to
12:20
Networking zone 1 (N1)
Lucas Wiessing
Bernd Schulte
Mads Uffe Pedersen
Hugo Faria
Catherine Comiskey
13:30
Short communication
Acute effects of cannabinoids on addiction endophenotypes are moderated by genes encoding the CNR1 receptor and FAAH enzyme
13:30
to
13:40
Networking zone 4 (N4)
Chandni Hindocha
Oral presentation
Use of contingency management (positive reinforcement with financial incentives) to encourage abstinence from heroin (PRAISE): a UK cluster randomised trial
13:30
to
13:45
Insights zone 4 (I4)
Nicola Metrebian
Timothy Weaver
Oral presentation
The off-prescription use of modafinil: an online survey of perceived risks and benefits
13:30
to
13:45
Insights zone 3 (I3)
Rachel Teodorini
Oral presentation
HepCATT (Hepatitis C Assessment to Treatment Trial) in primary care: a cluster RCT of whether a complex intervention based on risk prediction algorithm tool and education can increase testing and diagnosis of HCV in primary care
13:30
to
13:45
Insights zone 1 (I1)
Matthew Hickman
13:40
Short communication
Psychological aspects of cannabis use disorder: a review of the theory and implications for psychotherapy
13:40
to
13:50
Networking zone 4 (N4)
Daniel Feingold
13:45
Oral presentation
Opioid maintenance treatment (OMT) – not life-long for all women? 10 years follow-up after pregnancy - how many stop OMT and what are the results?
13:45
to
14:00
Insights zone 4 (I4)
Gabrielle Welle-Strand
Oral presentation
Prospective cohort to assess the impact of removing non-prescription codeine in Australia
13:45
to
14:00
Insights zone 3 (I3)
Jacqui McCoy
Oral presentation
Real-life effectiveness of direct-acting antiviral treatment among chronic hepatitis C infected opioid substituted patients in Germany
13:45
to
14:00
Insights zone 1 (I1)
Bernd Schulte
13:50
Short communication
Intention to reduce cannabis use and help-seeking attitudes in Dutch frequent cannabis users.
13:50
to
14:00
Networking zone 4 (N4)
Marleen Olthof
14:00
Short communication
Perceptions of effectiveness and believability of pictorial and text-only health warning labels for cannabis products among Canadian youth.
14:00
to
14:10
Networking zone 4 (N4)
Cesar Leos-Toro
Oral presentation
A look at the dark side of addiction treatment: a profile of those who drop out
14:00
to
14:15
Insights zone 4 (I4)
João Augusto
Oral presentation
Characteristics and problematic opioid use in people prescribed opioids for CNCP over four years: a prospective cohort study
14:00
to
14:15
Insights zone 3 (I3)
Gabrielle Campbell
Oral presentation
Hepatitis C Virus (HCV) elimination and the opioid crisis: joint problems, joint solution – results of a pilot programme
14:00
to
14:15
Insights zone 1 (I1)
Brian Conway
14:10
Short communication
Cannabis use in early adulthood and later prescription of antipsychotics, mood stabilisers, antidepressants and anxiolytics.
14:10
to
14:20
Networking zone 4 (N4)
Eline Rognli
14:15
Oral presentation
Methadone serum concentrations and influencing factors: a naturalistic observational study
14:15
to
14:30
Insights zone 4 (I4)
Fatemeh Chalabianloo
Oral presentation
A qualitative study of gabapentin use and misuse: perspectives of substance abuse treatment professionals
14:15
to
14:30
Insights zone 3 (I3)
Mance Buttram
Oral presentation
Service Integration: accessing HCV treatment for homeless PWIDs/ex-PWIDs attending community OST
14:15
to
14:30
Insights zone 1 (I1)
Tina McHugh
14:20
Short communication
Have chronic cannabis consumers developed tolerance to the residual effects of recent cannabis use?
14:20
to
14:30
Networking zone 4 (N4)
Raimondo Bruno
14:30
Short communication
Sociodemographic and educational characteristics of cannabis users attending outpatient treatment centres: implications for psychoeducational intervention
14:30
to
14:40
Networking zone 4 (N4)
Samuel Rueda
Oral presentation
Is methadone treatment more effective for lower socio-economic status opiate users? Results from a case crossover study in Lazio
14:30
to
14:45
Insights zone 4 (I4)
Antonella Camposeragna
Oral presentation
The cost-effectiveness of an HCV outreach intervention for at risk populations in London
14:30
to
14:45
Insights zone 1 (I1)
Zoe Ward
Oral presentation
Reduction in the population prevalence of chronic HCV among people who inject drugs associated with major scale-up of direct-acting antiviral therapy in community drug services: real world data
14:30
to
14:45
Insights zone 1 (I1)
Norah Palmateer
14:40
Short communication
Can cannabis use cause death in humans ?
14:40
to
14:50
Networking zone 4 (N4)
Mateja Jandl
15:10
Oral presentation
Growing up in a context of parental substance use: adult children's lived experiences on attachment and intergenerational transmition of trauma
15:10
to
15:25
Networking zone 2 (N2)
Florien Meulewaeter
15:25
Oral presentation
Examining the pathways for young people with drug and alcohol dependence following residential treatment: a data linkage study
15:25
to
15:40
Networking zone 2 (N2)
Sally Nathan
Sarita Bista
15:40
Oral presentation
The relationship between drugs and crime from the perspective of young people in contact with criminal justice systems. A qualitative, cross-national research.
15:40
to
15:55
Networking zone 2 (N2)
Franca Beccaria
15:55
Oral presentation
Substance use among college students in the Netherlands: a closer look at the prevalence of use and risk perception
15:55
to
16:10
Networking zone 2 (N2)
Arne van den Bos
16:10
Oral presentation
Unfolding social and material practices of drug treatment for youth in Azerbaijan and Germany
16:10
to
16:25
Networking zone 2 (N2)
Aysel Sultan
16:50
Oral presentation
A community-based peer-driven program to reach people who inject drugs, monitor risk behaviours and 'test and treat' for infectious diseases in Athens, Greece: ARISTOTLE HCV-HIV
16:50
to
17:05
Futures zone 1 (F1)
Vana Sypsa
Oral presentation
Modeling economical costs of alcohol consumption in Germany: the GECO-ALC1 project
16:50
to
17:05
Central square 3 (C3)
Jakob Manthey
17:00
Oral presentation
Cannabis use among people entering drug treatment. A growing phenomenon?
17:00
to
17:15
Insights zone 4 (I4)
Bruno Guarita
17:05
Oral presentation
Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage Study
17:05
to
17:20
Futures zone 1 (F1)
Jason Grebely
Oral presentation
Estimating substance use costs and harms in Canada
17:05
to
17:20
Central square 3 (C3)
Matthew Young
17:15
Oral presentation
Comparing adolescent and adult vulnerability to cannabis use problems
17:15
to
17:30
Insights zone 4 (I4)
Rachel Lees
17:20
Oral presentation
Low HCV-RNA prevalence and low anti HCV incidence in a large national sample of PWID in opioid substitution treatment in Germany: a prospective cohort study
17:20
to
17:35
Futures zone 1 (F1)
Bernd Schulte
Oral presentation
Morbi-mortality consequences of misuse of psychoactive prescription drugs in Portugal: a retrospective observational study - the MisuMedPT project
17:20
to
17:35
Central square 3 (C3)
Ana Araújo
17:30
Oral presentation
Cannabis and tobacco co-use: implications for addiction
17:30
to
17:45
Insights zone 4 (I4)
Chandni Hindocha
17:35
Oral presentation
Monitoring the elimination of hepatitis C and B among people who inject drugs in Europe
17:35
to
17:50
Futures zone 1 (F1)
Thomas Seyler
17:45
Oral presentation
Advances in the neurobiology of cannabis use disorders
17:45
to
18:00
Insights zone 4 (I4)
Valentina Lorenzetti
17:50
Oral presentation
'Towards eliminating viral hepatitis': A critical examination of the performativity of hepatitis C elimination goals and targets
17:50
to
18:05
Futures zone 1 (F1)
Kari Lancaster
18:00
Oral presentation
Cannabidiol: a novel treatment for cannabis cessation?
18:00
to
18:15
Insights zone 4 (I4)
Tom Freeman
18:05
Oral presentation
Evidencing viral elimination futures: modelling, targets and the end of Hep C
18:05
to
18:20
Futures zone 1 (F1)
Tim Rhodes
18:40
Short communication
Opioid-related problems in Baltic States and Poland: has the turning point come?
18:40
to
18:50
Networking zone 4 (N4)
Katri Abel-Ollo
18:50
Short communication
Estonia’s fentanyl battle: time to scale-up overdose prevention strategy?
18:50
to
19:00
Networking zone 4 (N4)
Sibella Hare Breidahl
19:00
Short communication
Assessment of possibilities for raising the quality of health care provided to opioid users by increasing access to substitution treatment
19:00
to
19:10
Networking zone 4 (N4)
Boguslawa Bukowska
19:10
Short communication
Rising incidence of ageing opioid users within the EU wide treatment
19:10
to
19:20
Networking zone 4 (N4)
Anne Marie Carew
19:20
Short communication
The neglected public health problem of opioid use among offenders - why we have failed and where we can improve.
19:20
to
19:30
Networking zone 4 (N4)
Friday, 25 October
10:45
Oral presentation
Young people's addictions treatment
10:45
to
12:15
Networking zone 4 (N4)
Deborah Judge
Lisa Mellen
10:55
Short communication
Single-gender groups for women suffering from opioid use fisorder: theory and treatment
10:55
to
11:05
Networking zone 3 (N3)
Efrat Fridma
Oral presentation
Systematic review of untreated remission from alcohol problems: estimation lies in the eye of the beholder
10:55
to
11:10
Insights zone 1 (I1)
Richard Mellor
11:05
Short communication
Systematic monitoring and feedback on data results as supportive tools for substance use disorder individuals
11:05
to
11:15
Networking zone 3 (N3)
Thomas Solgård Svendsen
11:10
Oral presentation
Assertive outreach for high-need, high-cost alcohol related frequent NHS hospital attenders: characteristics of participants in an RCT of assertive outreach treatment
11:10
to
11:25
Insights zone 1 (I1)
Andreas Kimergård
11:15
Short communication
Patient-centered care for addictions treatment: findings from a scoping review
11:15
to
11:25
Networking zone 3 (N3)
Kirsten Marchand
11:25
Short communication
OST futures: integrating the user’s experience into person-centred care
11:25
to
11:35
Networking zone 3 (N3)
Karen Black
Oral presentation
Applications of virtual reality and eye-tracking technologies in substance use disorders: the ALCO-VR project
11:25
to
11:40
Insights zone 1 (I1)
Alexandra Ghita
11:35
Short communication
Telephone delivered incentives for encouraging adherence to supervised methadone (TIES): development and feasibility study
11:35
to
11:45
Networking zone 3 (N3)
Nicola Metrebian
11:40
Impact of the introduction and withdrawal of financial incentives on the delivery of alcohol screening and brief advice in English primary health care: an interrupted time series analysis
11:40
to
11:55
Insights zone 1 (I1)
Amy O’Donnell
11:45
Short communication
Benzodiazepine use in an opioide maintenance programme: risks and clinical outcomes
11:45
to
11:55
Networking zone 3 (N3)
Catarina Oliveira
11:55
Short communication
Telephone-delivered contingency management to promote behaviour change in addiction treatment.
11:55
to
12:05
Networking zone 3 (N3)
Carol-Ann Getty
12:05
Short communication
Measuring personality problems in patients with substance use disorders
12:05
to
12:15
Networking zone 3 (N3)
Espen Ajo Arnevik